IRIS
RUMI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.637
AS - Asia 5.190
EU - Europa 3.662
SA - Sud America 819
Continente sconosciuto - Info sul continente non disponibili 411
AF - Africa 178
OC - Oceania 16
Totale 16.913
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.424
CN - Cina 2.185
SG - Singapore 1.149
IE - Irlanda 874
HK - Hong Kong 676
BR - Brasile 632
VN - Vietnam 573
RU - Federazione Russa 450
DE - Germania 396
FI - Finlandia 391
IT - Italia 370
FR - Francia 310
UA - Ucraina 290
GB - Regno Unito 160
SE - Svezia 152
IN - India 111
CA - Canada 100
BD - Bangladesh 98
ZA - Sudafrica 68
AR - Argentina 66
MX - Messico 66
IQ - Iraq 45
AT - Austria 44
NL - Olanda 43
PK - Pakistan 43
TR - Turchia 39
PL - Polonia 38
CO - Colombia 34
JP - Giappone 34
ID - Indonesia 33
RO - Romania 29
MA - Marocco 27
MY - Malesia 27
ES - Italia 24
SA - Arabia Saudita 22
VE - Venezuela 21
EC - Ecuador 20
UZ - Uzbekistan 18
JO - Giordania 17
CL - Cile 16
PY - Paraguay 16
EG - Egitto 15
PH - Filippine 15
AU - Australia 14
BE - Belgio 14
KE - Kenya 14
AE - Emirati Arabi Uniti 13
JM - Giamaica 12
LT - Lituania 12
CZ - Repubblica Ceca 11
NP - Nepal 10
AZ - Azerbaigian 9
TN - Tunisia 9
IL - Israele 8
KZ - Kazakistan 8
DZ - Algeria 7
EU - Europa 7
LB - Libano 7
MU - Mauritius 7
NI - Nicaragua 7
AL - Albania 6
CH - Svizzera 6
CR - Costa Rica 6
OM - Oman 6
UY - Uruguay 6
ET - Etiopia 5
KG - Kirghizistan 5
KR - Corea 5
LA - Repubblica Popolare Democratica del Laos 5
LV - Lettonia 5
PA - Panama 5
PT - Portogallo 5
RS - Serbia 5
TH - Thailandia 5
AM - Armenia 4
GR - Grecia 4
HN - Honduras 4
LK - Sri Lanka 4
NG - Nigeria 4
PE - Perù 4
QA - Qatar 4
XK - ???statistics.table.value.countryCode.XK??? 4
BO - Bolivia 3
DO - Repubblica Dominicana 3
GD - Grenada 3
GE - Georgia 3
MD - Moldavia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
CG - Congo 2
DK - Danimarca 2
GA - Gabon 2
GT - Guatemala 2
HU - Ungheria 2
KH - Cambogia 2
Totale 16.480
Salva come PNG Salva come JPEG
Città #
Dublin 873
San Jose 686
Hong Kong 662
Ashburn 646
Chandler 643
Singapore 558
Dallas 535
Jacksonville 426
Nanjing 394
Beijing 388
Boardman 262
Lauterbourg 242
Council Bluffs 237
Ho Chi Minh City 195
Los Angeles 175
Princeton 167
Nanchang 164
New York 161
Lawrence 158
Helsinki 138
Hanoi 123
Wilmington 121
Shenyang 118
Changsha 116
Hebei 110
Medford 101
Munich 97
Jiaxing 91
Santa Clara 85
Shanghai 84
Buffalo 80
Ann Arbor 79
Tianjin 77
Moscow 69
Hangzhou 63
Redondo Beach 63
São Paulo 56
Johannesburg 53
Milan 51
Orem 43
Pavia 41
Nuremberg 39
Toronto 36
Seattle 35
Da Nang 34
Turku 34
Rome 33
Columbus 31
Brooklyn 30
Frankfurt am Main 30
Tokyo 30
Denver 29
Haiphong 29
Warsaw 29
Woodbridge 29
Norwalk 28
Chennai 25
Falkenstein 24
Mexico City 24
Montreal 23
San Francisco 23
Stockholm 22
The Dalles 22
Timisoara 22
Washington 22
Chicago 20
Vienna 20
Boston 19
Houston 19
Guangzhou 18
Rio de Janeiro 18
Atlanta 17
London 17
Fairfield 16
Amman 15
Baghdad 15
Hải Dương 15
Manchester 15
Tashkent 15
Brussels 14
Jinan 14
Poplar 14
Verona 14
Zhengzhou 14
Curitiba 13
Florence 13
Rawalpindi 13
Buenos Aires 12
Phoenix 12
Ankara 11
Auburn Hills 10
Belo Horizonte 10
Bogotá 10
Catania 10
Charlotte 10
Kuala Lumpur 10
Lahore 10
Prague 10
Amsterdam 9
Biên Hòa 9
Totale 10.595
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 191
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 179
An insidious presentation of splenic marginal zone lymphoma 160
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 156
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 149
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 147
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 146
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 146
Blast phase of essential thrombocythemia: A single center study. 145
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 144
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 139
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 138
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 135
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 133
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 131
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 131
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 131
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 128
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 125
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 121
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 121
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 121
Clinical significance of somatic mutation in unexplained blood cytopenia 120
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 120
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 119
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 119
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 116
Acute arterial and deep venous thromboembolism in COVID-19 patients: Risk factors and personalized therapy 115
JAK2 (V617F) mutation in healthy individuals 113
Diagnosis and management of prefibrotic myelofibrosis. 113
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 111
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 110
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 110
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 109
Allelic imbalance in CALR somatic mutagenesis 108
A journey through infectious risk associated with ruxolitinib. 108
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 108
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 107
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 107
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 106
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 106
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 105
Somatic mutations of calreticulin in myeloproliferative neoplasms 105
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 103
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 103
Facing erythrocytosis: Results of an international physician survey. 103
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 101
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 101
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 101
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 100
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 100
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 100
Role of the molecular staging and response in the management of follicular lymphoma patients 99
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 99
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 98
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 98
Clinical relevance of JAK2 (V617F) mutant allele burden 97
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. 97
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 97
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 97
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 95
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 95
Familial chronic myeloproliferative disorders: the state of the art 94
Cardiovascular events and intensity of treatment in polycythemia vera. 94
Peripheral intraneutrophil diplococci in a case of meningococcemia. 94
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 94
Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). 94
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. 93
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 93
COVID-19 in Patients with Hematologic Diseases 92
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 92
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 92
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms 91
Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver 91
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. 91
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 90
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 90
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 90
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 90
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 90
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms 89
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 89
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 89
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 88
Mutations and prognosis in primary myelofibrosis 88
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 88
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 88
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib 87
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 86
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 86
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 86
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 86
Improving survival trends in primary myelofibrosis: an international study. 86
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. 83
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 83
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 82
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 82
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. 81
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms 81
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 81
Totale 10.700
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.525
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.525
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022683 0 4 23 11 17 38 6 38 33 38 115 360
2022/20232.087 222 118 21 135 204 169 1 100 989 13 87 28
2023/20241.049 119 170 55 69 96 297 27 66 10 22 76 42
2024/20252.759 66 208 72 61 56 120 198 204 641 114 370 649
2025/20266.755 497 556 786 788 723 311 1.281 239 587 518 250 219
2026/2027417 125 292 0 0 0 0 0 0 0 0 0 0
Totale 16.913